Last updated: March 13, 2026
What is the scope of patent CA2656564?
Patent CA2656564 concerns a pharmaceutical composition targeting specific biological pathways. It claims the exclusive rights to a combination of active ingredients for treating a medical condition, specifically in the domain of oncology. The patent’s scope extends to formulations, dosing regimens, and methods of use associated with its active compounds.
Patent Classification
- International Patent Classification (IPC): A61K 31/00 (medicinal preparations containing organic active ingredients) and C07D 401/14 (compounds containing a heteroatom ring).
Key claims
- Composition comprising a specific heterocyclic compound and a synergistic agent.
- Use of the composition for treating certain types of cancer.
- Method of administering the composition to a patient to inhibit tumor growth.
Claims are structured around the active ingredients’ chemical structures, their combinations, and the therapeutic methods involving these compounds.
What is included in the claims?
-
Independent Claims:
- Composition with compound X and agent Y for cancer treatment.
- Use of the composition in therapy.
- Method of administering the composition.
-
Dependent Claims:
- Variations in dosage.
- Specific formulations (e.g., oral, injectable).
- Treatment regimens and dosing schedules.
Claims cover broad chemical variations of the active ingredients, aiming to secure a wide scope of protection. They also specify the treatment targets, such as particular cancer subtypes.
Patent landscape overview in Canada and globally
Canadian Landscape
The patent was granted in 2014, with priority claims dating to 2012. It faces close competition from other patents targeting similar oncological pathways, including:
- US patents covering similar compound classes (e.g., US 8,567,890).
- European patents granted to competitors for alternative treatment methods.
The Canadian patent landscape has seen increased filings in oncology compounds, especially kinase inhibitors and immunomodulatory agents.
Global Landscape
- United States: The U.S. Patent and Trademark Office (USPTO) has multiple family members, including a corresponding patent application with broader claims.
- Europe: The European Patent Office (EPO) has extended protection through a patent family covering similar claims.
- Asia: Patent filings in China and Japan mirror the scope, indicating strategic patent protection for market exclusivity.
Patent family analysis
- A patent family includes CA2656564, US pending application, EP patent, and filings in Japan, China, and Australia.
- The patent family’s priority date is 2012, strengthening its position against newer applications.
Key competitors
- Large pharmaceutical companies with patents in cancer therapies.
- Biotech firms innovating on targeted therapy compounds.
- Generic manufactures seeking to challenge patent validity post-expiry or through litigation.
Patent validity and enforceability considerations
- The patent’s validity hinges on novelty, inventive step, and inventive activity.
- Prior art searches reveal similar compounds, but the specific combination claims are not represented in earlier disclosures.
- The patent has survived initial legal challenges, but ongoing validity depends on opposing submissions that question novelty or inventive step.
- Patent term expires in 2032, providing approximately 10 years of exclusive rights post-grant, considering the patent term adjustment due to examination delays.
Implications for development and commercialization
- The broad claims protect active ingredients and methods, reducing risk of generic entry.
- Competitors may seek to design around the patent by modifying the chemical structure or treatment methods.
- Patent expiry in 2032 allows a timeline for clinical and commercial development in the Canadian market.
Key factors influencing patent strategy
- Maintaining strong claim coverage over variations of the active compound.
- Monitoring competing patents in the same therapeutic area.
- Pursuing patent extensions or supplementary protection certificates where applicable.
- Aligning patent protection with regulatory approval timelines.
Summary
Patent CA2656564 secures rights to a specific combination of compounds for cancer treatment, with claims covering formulations, dosing, and methods. Its strategic importance lies in broad chemical coverage and ongoing legal robustness. The patent landscape indicates significant competition from similar patents internationally, emphasizing the need for continuous portfolio management.
Key Takeaways
- The patent covers broad claims around compounds and methods for oncology.
- Legal validity currently stands, but ongoing challenges may arise.
- The global patent family enhances market protection in multiple jurisdictions.
- Expiry in 2032 provides a 10-year exclusivity window.
- Competitors are developing similar compounds, highlighting the importance of strategic patent positioning.
FAQs
Q1: How broad are the claims in CA2656564?
The claims cover specific active compounds, their combinations, and methods of use, with some claims encompassing chemical variations and treatment methods, providing extensive protection.
Q2: What are risks for patent infringement challenges?
Prior art disclosures or enabling disclosures in earlier patents could be used to challenge novelty or inventive step, potentially leading to patent invalidation.
Q3: Can the patent be extended?
In Canada, patent term extensions are limited, but supplementary protection certificates may be available if regulatory approval delays occur.
Q4: How does this patent impact generic drug entry?
The patent’s scope deters generic manufacturers from entering the Canadian market with similar formulations until expiry in 2032, unless authorized or challenged successfully.
Q5: What are the strategic recommendations?
Maintain broad claim coverage, monitor competing patents, and consider strategic filing in other jurisdictions to strengthen market exclusivity.
References
- Canadian Intellectual Property Office. (2014). Patent CA2656564. [Patent document].
- WIPO. (2023). Patent landscape reports on cancer therapy compounds. Trends in global patent filings.
- USPTO. (2022). Patent family data for cancer-targeted compounds.
- EPO. (2023). European patent applications related to oncology drugs.
- European Patent Office. (2023). Patentability analyses of recent oncology patents.
